U-CyTech/Human IFN-γ T cell ELISPOT kit/2-plate/CT230-PB2

References list

• Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.
  Botta, Cirino, et al. J. Immunother. 2012 Jun;35: 440-7
• Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy.
  Chiriva-Internati, Maurizio, et al. J. Immunother. 2011 Jul-Aug;34: 490-9
• Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer.
  Chiriva-Internati, Maurizio, et al. Prostate 2012 Jan;72: 12-23
• Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.
  Correale, P, et al. Int. J. Cancer 2012 Apr 01;130: 1577-89
• Chromogranin A is a T cell antigen in human type 1 diabetes.
  Gottlieb, Peter A, et al. J. Autoimmun. 2014 May;50: 38-41
• Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses.
  Honegger, Jonathan R, et al. Nat. Med. 2013 Nov;19: 1529-33
• Influence of IFNL3 and HLA-DPB1 genotype on postpartum control of hepatitis C virus replication and T-cell recovery.
  Honegger, Jonathan R, et al. Proc. Natl. Acad. Sci. U.S.A. 2016 09 20;113: 10684-9
• A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.
  Mendell, Jerry R, et al. Mol. Ther. 2015 Jan;23: 192-201
• Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets.
  Mirandola, Leonardo, et al. Oncotarget 2015 Feb 20;6: 2812-26
• Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes.
  Ostrov, David A, et al. J. Clin. Invest. 2018 May 01;128: 1888-1902
• Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro.
  Shi, M, et al. Clin. Exp. Immunol. 2007 Feb;147: 277-86